GEN Exclusives

More »

GEN News Highlights

More »
Nov 6, 2007

Varian Purchases Analogix for $11M to Bolster Lab Consumables Offerings

  • Varian acquired Analogix for approximately $11 million in cash. The transaction also includes future milestone fees over three years that could reach $4 million.

    Varian says that it decided to buy Analogix to strengthen its product portfolio especially in the area of laboratory consumables. Analogix focuses on the development of prepacked columns and instrumentation for automated compound purification using flash chromatography.

    “The acquisition of Analogix is strategic to the advancement of Varian's goal to grow applications-based consumables products and to further broaden its product offering to the pharmaceutical industry,” comments Garry Rogerson, president and CEO, Varian. “Analogix has demonstrated an ability to successfully meet customer needs in the area of drug discovery and to grow its business rapidly in North America. Analogix products will now be distributed more effectively on a global basis via Varian's worldwide distribution network.”


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »